Eisai Europe Limited is a limited company established in 2004, operating from its European Knowledge Centre in Hatfield, England, AL10 9SN. The company’s core business centers around the development, manufacturing, and commercialization of innovative pharmaceutical products. Eisai Europe focuses primarily on providing specialized therapies for patients with neurological disorders, including multiple sclerosis and amyotrophic lateral sclerosis (ALS). As a regulated entity, Eisai Europe operates under the SIC codes - 70100 (Head Office Activities) and 74909 (Other Professional, Scientific, and Technical Activities). The company’s activities encompass research, clinical trials, regulatory submissions, and commercialization across Europe. Eisai Europe’s primary focus is on enhancing patient outcomes through the delivery of novel therapies. The company’s international presence is significant, with a dedicated team operating across multiple European countries. Currently, Eisai Europe is a skilled worker, holding a Worker (A) rating, indicating a focus on specialized roles within the pharmaceutical industry. The company’s key focus is on improving the quality of life for individuals affected by neurological diseases.

Eisai Europe Limited is a limited company established in 2004, operating from its European Knowledge Centre in Hatfield, England, AL10 9SN. The company’s core business centers around the development, manufacturing, and commercialization of innovative pharmaceutical products. Eisai Europe focuses primarily on providing specialized therapies for patients with neurological disorders, including multiple sclerosis and amyotrophic lateral sclerosis (ALS). As a regulated entity, Eisai Europe operates under the SIC codes - 70100 (Head Office Activities) and 74909 (Other Professional, Scientific, and Technical Activities). The company’s activities encompass research, clinical trials, regulatory submissions, and commercialization across Europe. Eisai Europe’s primary focus is on enhancing patient outcomes through the delivery of novel therapies. The company’s international presence is significant, with a dedicated team operating across multiple European countries. Currently, Eisai Europe is a skilled worker, holding a Worker (A) rating, indicating a focus on specialized roles within the pharmaceutical industry. The company’s key focus is on improving the quality of life for individuals affected by neurological diseases.